Health / Nigeria

Nigeria’s disease burden outpaces clinical trials, UNILAG warns

Nigeria’s disease burden outpaces clinical trials, UNILAG warns

By Chioma Obinna

Nigeria’s quest for improved healthcare delivery and reduced dependence on imported medicines and medical products may remain elusive without urgent investment in biomedical research, clinical trials and local innovation, the University of Lagos has warned.

The Vice Chancellor of the university, Professor Folasade Ogunsola, said Nigeria must strengthen its clinical research capacity to develop treatments that address the peculiar health needs of its population, warning that scientific discoveries must move beyond laboratories to produce practical healthcare solutions and economic benefits.


Ogunsola spoke yesterday at the 12th Annual Scientific Conference of the Faculty of Basic Medical Sciences, College of Medicine, UNILAG, Idi-Araba, Lagos, where experts called for stronger research institutions, sustainable funding and closer collaboration between universities, industry, and government.


The warning comes amid concerns that Africa, despite carrying about 24 per cent of the global disease burden, remains significantly underrepresented in clinical trials and the development of medical innovations.


The Vice Chancellor argued that research should not be seen merely as an academic exercise but as a major instrument for economic development, job creation and national competitiveness.


Citing global technology companies and medical innovations that emerged from research investments, she said patents, royalties and intellectual property from scientific discoveries could create new businesses, generate employment and strengthen the economy.


Ogunsola said: “The patents and royalties and IPs from new products can make research huge and make it an economic development tool.”


She explained that clinical trials were critical because treatments developed and tested largely outside Africa might not adequately address the biological and genetic differences of African populations.


“We are not Caucasians. And most clinical trials have been done on Caucasians. The way diabetes affects us, the way high blood pressure affects us, the way cardiovascular disease affects us, is different from the way it affects Caucasians or from the way it affects people in high-income countries,” she said.


According to her, the use of medicines without adequate testing in the populations expected to benefit from them could undermine treatment outcomes.


“Sometimes you wonder why you’re using something for cancer in these patients and it’s not working. It’s not working because it wasn’t tested in people like him or her,” she added.


The Vice Chancellor maintained that Nigeria must develop its own research and clinical trial capacity to generate evidence, produce innovations and respond more effectively to disease outbreaks.


She also explained that clinical trials were not limited to testing medicines but covered vaccines, diagnostic tests, medical devices, preventive interventions and healthcare delivery procedures.


Ogunsola, who highlighted the contribution of clinical research to the development of treatments for sickle cell disease and other conditions, said research findings must be translated into policies and interventions that reach patients.


She, however, expressed concern about the long delay between scientific discoveries and their adoption in routine healthcare, noting that the process could take about 17 years.


She said Nigeria must build stronger links between basic research, clinical trials, implementation science and healthcare policy to prevent valuable discoveries from remaining unused.


Also speaking, Dr Kwaku Baryeh, Director of Clinical Chemistry at Eli Lilly and Company, Indiana, United States, said Africa’s enormous disease burden was not reflected in its contribution to global clinical research.


Baryeh argued that the problem was not a shortage of scientific talent but the absence of adequately funded systems capable of translating research questions into treatments and products.


“The problem that we have here is not a lack of talent, but a lack of asking the right questions and having a system that translates those questions into treatment, into products that will reach patients in Accra, that will reach patients in Lagos, that will reach patients around the world,” he said.


He stressed that African researchers must take the lead in setting research priorities based on the continent’s disease burden rather than relying on research agendas developed elsewhere.


According to him, conditions such as sickle cell disease, diabetes, cancer and other chronic illnesses should feature prominently in Africa’s research priorities.


Baryeh said Nigeria had demonstrated its scientific capacity during disease outbreaks, recalling the country’s containment of the 2014 Ebola outbreak and the sequencing of the first COVID-19 genome in Nigeria within days of the country’s first confirmed case in 2020.


“When Nigerian scientists are properly resourced, organised and trusted, they can operate at world-class level. Our task is to make sure that this becomes the rule and not an exception,” he said.


He called for improved laboratory infrastructure, equipment maintenance, staff training, quality assurance and sustainable research funding.


The Eli Lilly director also advocated stronger collaboration across scientific disciplines, arguing that biomedical research required the combined expertise of biochemists, physiologists, clinicians, data scientists, engineers and health economists.


On artificial intelligence, Baryeh urged universities and research institutions to integrate emerging technologies into scientific training and research, while ensuring that African data and populations were adequately represented in the development of medical technologies.


He further called for stronger technology transfer mechanisms and local manufacturing of medicines, vaccines and diagnostic products, saying these were essential to Africa’s health sovereignty.


The Managing Director and Chief Executive Officer of the Nigerian Railway Corporation, Dr Isiak Kayode Opeifa, challenged young scientists to move beyond academic publications and turn their research findings into commercially viable products.
Opeifa, an alumnus of the College of Medicine, UNILAG, drew from his experience in the United States’ biotechnology and pharmaceutical industries to explain how laboratory discoveries could become valuable commercial products.


He urged researchers not to allow their findings to remain on university shelves when they could attract investment and solve real-life problems.


“We have to move from the lab to the market,” he said.


According to him, Nigeria has researchers with the requisite knowledge and scientific training, but inadequate practical exposure, equipment and funding often limit their ability to compete internationally.


He recalled that access to advanced laboratory equipment and additional technical training helped shape his career, urging students to take advantage of opportunities for continuous learning and practical skills development.


Opeifa also encouraged young scientists to explore opportunities beyond the classroom and laboratory, including emerging technologies and multidisciplinary research.


He said: “These days, the whole world is here. It’s on the phone. Take advantage and take some classes.”


He further urged researchers to embrace computer literacy, artificial intelligence and collaboration across disciplines, stressing that scientific knowledge must be applied to solve problems and create value.


The conference, themed Strengthening Biomedical Sciences for Innovation and Effective Research Outcomes: Strategies for Improved Healthcare, underscored the need for stronger research institutions, sustainable funding, industry partnerships and investment in the next generation of scientists.


The speakers agreed that Nigeria’s ability to improve healthcare outcomes would depend not only on generating scientific knowledge but also on developing the institutional capacity to transform discoveries into affordable treatments, diagnostic tools and locally manufactured medical products.

Share this story WhatsApp Facebook X
Originally published by Vanguard
View on Vanguard

Comments 0

No comments yet. Start the conversation.

Loading the next story…